Sage Therapeutics Stock News

Equities research analysts expect Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings per share (EPS) of ($2.15) for the current fiscal quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for Sage Therapeutics earnings, with estimates ranging from ($2.41) to ($1.67). Sage Therapeutics reported earnings per share of ($2.47) during the same quarter last []

Sage Therapeutics, Inc. (NASDAQ:SAGE)s stock price gapped down before the market opened on Monday . The stock had previously closed at $40.90, but opened at $39.69. Sage Therapeutics shares last traded at $40.21, with a volume of 837 shares traded. Several equities research analysts have recently commented on SAGE shares. Stifel Nicolaus decreased their price []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET. A live webcast of the fireside chat can be accessed on the Investor page of Sages website at investor

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Sage Therapeutics (NASDAQ:SAGE)s stock had its buy rating reaffirmed by analysts at Needham & Company LLC in a research note issued on Thursday, Price Targets.com reports. They presently have a $78.00 price objective on the biopharmaceutical companys stock. Needham & Company LLCs target price would suggest a potential upside of 90.71% from the companys previous []

Sage Therapeutics (NASDAQ:SAGE) had its price objective cut by Mizuho from $52.00 to $44.00 in a research note issued to investors on Thursday, The Fly reports. They currently have a neutral rating on the biopharmaceutical companys stock. SAGE has been the subject of a number of other reports. Stifel Nicolaus cut their price target on []

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

SAGE Therapeutics, Inc. (SAGE) CEO Barry Greene on Q3 2021 Results - Earnings Call Transcript

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -20.11% and -28.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debili

Sage Therapeutics (NASDAQ:SAGE) shares are trading higher after the company announced it received Fast Track Designation for SAGE-718 or the treatment of Huntington's disease. Sage Therapeutics is cu